Suppr超能文献

孕期美沙酮与丁丙诺啡/纳洛酮对围产期和新生儿健康结局的比较效果:加拿大不列颠哥伦比亚省一项基于人群的目标试验方案

Comparative effectiveness of methadone versus buprenorphine/naloxone during pregnancy on perinatal and neonatal health outcomes: protocol for a population-based target trial in British Columbia, Canada.

作者信息

Wilson Lindsay A, Kurz Megan, Guerra-Alejos B Carolina, Min Jeong Eun, Ti Lianping, Nosyk Bohdan

机构信息

School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.

Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada.

出版信息

BMJ Open. 2025 Aug 10;15(8):e095461. doi: 10.1136/bmjopen-2024-095461.

Abstract

INTRODUCTION

Opioid use disorder (OUD) during pregnancy is associated with increased rates of adverse perinatal, foetal and neonatal health events. Opioid agonist treatment (OAT) can substantially reduce the risk of these potential harms. In British Columbia (BC), methadone and buprenorphine/naloxone are first-line treatment options for pregnant people with OUD. However, the comparative effectiveness of these regimens during pregnancy remains poorly understood, particularly in terms of how dosage may impact clinical outcomes. This protocol outlines a proposed population-based retrospective study to evaluate the comparative effectiveness of methadone compared with buprenorphine/naloxone during pregnancy on perinatal and neonatal health outcomes.

METHODS AND ANALYSIS

We propose to conduct a retrospective observational study using population-based data from individuals who received methadone or buprenorphine/naloxone during pregnancy between 1 April 2010 and 31 March 2022. Data will be collected from 10 linked population-level administrative databases. We will emulate target trials using intention-to-treat and per-protocol approaches. We will use a pooled logistic regression approach to assess the impact of methadone versus buprenorphine/naloxone on time to OAT episode discontinuation and a dose-response marginal structural model to evaluate neonatal health at delivery. An exploratory observational analysis will also be conducted to describe the impact of methadone vs buprenorphine exposure during the first trimester of pregnancy on congenital malformations and anomalies.

ETHICS AND DISSEMINATION

This study has been determined to meet the criteria for exemption per Article 2.5 of the 2018 Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. Study databases have been made available by the BC Ministries of Health and Mental Health and Addiction as part of the provincial opioid overdose public health emergency response. Results will be disseminated to policymakers, clinical partners, community programmes and people with lived and living experience of substance use and published in peer-reviewed journals.

摘要

引言

孕期阿片类药物使用障碍(OUD)与围产期、胎儿和新生儿不良健康事件发生率增加有关。阿片类激动剂治疗(OAT)可大幅降低这些潜在危害的风险。在不列颠哥伦比亚省(BC),美沙酮和丁丙诺啡/纳洛酮是患有OUD的孕妇的一线治疗选择。然而,这些治疗方案在孕期的相对有效性仍知之甚少,尤其是剂量如何影响临床结果方面。本方案概述了一项拟议的基于人群的回顾性研究,以评估孕期美沙酮与丁丙诺啡/纳洛酮在围产期和新生儿健康结局方面的相对有效性。

方法与分析

我们建议使用2010年4月1日至2022年3月31日期间孕期接受美沙酮或丁丙诺啡/纳洛酮治疗的个体的基于人群的数据进行回顾性观察研究。数据将从10个相互关联的人群层面行政数据库中收集。我们将采用意向性治疗和符合方案的方法模拟目标试验。我们将使用汇总逻辑回归方法评估美沙酮与丁丙诺啡/纳洛酮对OAT疗程停药时间的影响,并使用剂量反应边际结构模型评估分娩时的新生儿健康状况。还将进行探索性观察分析,以描述孕期头三个月美沙酮与丁丙诺啡暴露对先天性畸形和异常的影响。

伦理与传播

本研究已确定符合2018年三理事会政策声明第2.5条《涉及人类研究的伦理行为》规定的豁免标准。作为该省阿片类药物过量公共卫生应急响应的一部分,BC省卫生、心理健康和成瘾部提供了研究数据库。研究结果将传播给政策制定者、临床合作伙伴、社区项目以及有物质使用亲身经历的人,并发表在同行评审期刊上。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3112/12336511/f1d12fd76c28/bmjopen-15-8-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验